ArticleCureus2026
Necrotizing Soft Tissue Infection at a Self-Administered Subcutaneous Etanercept Injection Site in an Immunosuppressed Patient With Rheumatoid Arthritis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Giant Abdominal Haematoma and Rapid Multidrug-Resistant Infection After Low-Molecular-Weight Heparin in a Patient With COVID-19 and Rheumatoid Arthritis.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing soft tissue infection (NSTI) is rapidly progressive and can be fatal; outcomes depend on early recognition and prompt surgical debridement. In immunocompromised patients, local findings and inflammatory responses may be atypical, increasing the risk of delayed diagnosis. Although injections breach the skin barrier, NSTI originating at injection sites can be overlooked as a benign injection-site reaction; procedure-associated NSTI has been reported to have poor outcomes. A woman in her 60s with rheumatoid arthritis was receiving methotrexate, tacrolimus, and prednisolone and had started self-administered subcutaneous etanercept injections four months earlier. One week prior to presentation, she developed discomfort and mild pain in the medial right thigh at her usual injection site, and, presuming it was a routine injection-site reaction, delayed medical attention. She presented with fever and difficulty walking and was transferred to our hospital in septic shock. Examination revealed ill-defined erythema and swelling without overt skin necrosis, but pain was disproportionately severe. Contrast-enhanced computed tomography (CT) showed fascial thickening and deep soft-tissue edema without gas. Given a strong clinical suspicion for NSTI, emergent surgical exploration (finger test) and debridement were performed, confirming necrosis of the subcutaneous tissue and fascia. Group A β-hemolytic streptococcus (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.